MindMaze Therapeutics (SIX: MMTX) reported new real-world evidence from a multi-site program with Vibra Healthcare showing that home-based rehabilitation using MindMotion increased total motor-training dose by a median factor of three compared with usual outpatient therapy alone. The findings, presented at the American Congress of Rehabilitation Medicine in Washington, DC, are particularly relevant as the company prepares to launch MindMotion Lite by year-end 2026.
The retrospective quality improvement program evaluated 177 rehabilitation episodes involving 172 adults with neurological conditions, primarily stroke, across four Vibra Healthcare outpatient sites. Participants followed an eight-week home-training program using MindMotion GO, with optional four-week extension and periodic therapist supervision. Results showed that 84.4% of active training was completed asynchronously, without direct therapist supervision, and patients averaged 174 minutes of active training per week. Functional outcomes improved significantly: Barthel Index scores rose by 10.4 points, Berg Balance Scale by 10.5 points, SLUMS cognition scores by 3.4 points, and Timed Up and Go mobility improved by 8.8 seconds. High engagement was observed, with 92.7% successfully completing home setup, 80.2% achieving minimum training exposure, and 83.8% of satisfaction ratings positive.
These results build on previously reported inpatient findings with Vibra Healthcare and support MindMaze's strategy to extend high-dose, high-intensity neurorehabilitation into patients' homes. The upcoming Recently announced MindMotion Lite is a tablet-based solution designed to deliver the full range of MindMotion GO activities with reduced hardware, simplifying home deployment and supporting broader adoption. The full poster is available at mindmazetherapeutics.com/mindmaze-platform/clinical-evidence.
“Earlier this year, we showed that MindMaze's high-dose, high-intensity therapy, integrated into inpatient rehabilitation, delivers superior functional outcomes in a resource-efficient way,” said Zach Henderson, CEO of MindMaze Therapeutics. “Now, we are demonstrating that this value can extend into the home to address a well-recognized gap in care once patients leave the clinic, in line with the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery. These results, combined with our upcoming MindMotion Lite tablet-based solution, will help make high-quality neurotherapeutics more accessible. Together, these milestones bring us closer to our mission of making neurotherapeutics available at scale.”
The implications are significant for a healthcare system facing a shortage of specialized clinicians. By enabling high-dose training at home with minimal supervision, MindMaze's approach could reduce the burden on outpatient therapy and improve access for patients in remote or underserved areas. The company's FDA-listed and CE-marked products are designed to address this shortage, offering scalable, reimbursable solutions for stroke, Parkinson's disease, and other neurological disorders. As MindMaze Therapeutics (SIX: MMTX) continues to validate its platform, the home-based results reinforce the potential for digital neurotherapeutics to transform rehabilitation and recovery trajectories for patients worldwide. For more information, visit www.mindmazetherapeutics.com.
